Dupilumab for the treatment of atopic dermatitis: A clinical trial review
- 15 July 2015
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 15 (11), 1657-1660
- https://doi.org/10.1517/14712598.2015.1076388
Abstract
Current treatment options for moderate-to-severe atopic dermatitis (AD) are limited and have potentially dangerous side effects. Dupilumab is a novel monoclonal antibody that was recently studied in adult patients with moderate-to-severe AD. Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma. Considering that both AD and asthma are Th2 cell-mediated inflammatory processes, it is reasonable to suspect that dupilumab would be beneficial in AD.`This publication has 9 references indexed in Scilit:
- Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitisJournal of Allergy and Clinical Immunology, 2014
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic DermatitisThe New England Journal of Medicine, 2014
- Persistence of Mild to Moderate Atopic DermatitisJAMA Dermatology, 2014
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014
- Molecular Biology of Atopic DermatitisClinical Reviews in Allergy & Immunology, 2014
- Adult eczema prevalence and associations with asthma and other health and demographic factors: A US population–based studyJournal of Allergy and Clinical Immunology, 2013
- Dupilumab in Persistent Asthma with Elevated Eosinophil LevelsThe New England Journal of Medicine, 2013
- A randomized trial of methotrexate versus azathioprine for severe atopic eczemaJournal of Allergy and Clinical Immunology, 2011
- A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitisBritish Journal of Dermatology, 2005